| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:10548101 | IVR | 0.0024 mg/kg | 0.0024 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Accelerated onset of puberty | Reproductive endocrine-mediated perturbations | |
| PMID:10597890 | IVR | 0.5 mg/L | - | No significant effects observed | - |
| IVR | 50 mg/L | 50 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| PMID:10746942 | IVR | 100 mg/kg | - | No significant effects observed | - |
| IVR | 400 mg/kg | 400 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:10825674 | IVR | 25 mg/kg | - | No significant effects observed | - |
| IVR | 50 mg/kg | 50 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 12.5 mg/kg | - | No significant effects observed | - | |
| IVR | 100 mg/kg | 100 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| PMID:10828501 | IVR | 1000 mg/kg/day | 1000 mg/kg/day | Oxidative stress in uterus | Reproductive endocrine-mediated perturbations |
| PMID:10839476 | IVR | 128 mg/kg/day | 128 mg/kg/day | Increased prolactin levels | Reproductive endocrine-mediated perturbations |
| IVR | 128 mg/kg/day | 128 mg/kg/day | Affects uterine development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 128 mg/kg/day | 128 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 128 mg/kg/day | 128 mg/kg/day | Affects pituitary gland development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 250 mg/kg/day | 250 mg/kg/day | Affects uterine development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 250 mg/kg/day | 250 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 250 mg/kg/day | 250 mg/kg/day | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 78 mg/kg/day | 78 mg/kg/day | Affects uterine development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 78 mg/kg/day | 78 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 11 mg/kg/day | 11 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 11 mg/kg/day | 11 mg/kg/day | Affects uterine development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:11474214 | IVR | 10 mg | 10 mg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:11896564 | IVR | 50 mg/kg | 50 mg/kg | Affects differentiation process | Developmental endocrine-mediated perturbations |
| IVR | 50 mg/kg | 50 mg/kg | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| PMID:11914775 | IVR | 40 mg/kg | - | No significant effects observed | - |
| IVR | 600 mg/kg | 600 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations | |
| PMID:12060837 | IVR | 0.04 mg/kg | 0.04 mg/kg | Altered lordosis | Developmental endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:12148547 | IVR | 0.000002 mg/wt/day | 0.000002 mg/wt/day | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.000002 mg/wt/day | 0.000002 mg/wt/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000002 mg/wt/day | 0.000002 mg/wt/day | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000002 mg/wt/day | 0.000002 mg/wt/day | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000002 mg/wt/day | 0.000002 mg/wt/day | Reduced sperm quality | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00002 mg/wt/day | 0.00002 mg/wt/day | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00002 mg/wt/day | 0.00002 mg/wt/day | Reduced sperm quality | Reproductive endocrine-mediated perturbations | |
| PMID:12151630 | IVR | 50 mg/kg | 50 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg | 50 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| PMID:12206822 | IVTH | 0.00000000003 - 0.0000001 M | 0.00000000003 - 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00000000003 - 0.0000001 M | 0.000000001 - 0.00000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| PMID:12230427 | IVR | 0.5 mg/day | 0.5 mg/day | Affects liver function | Hepatic endocrine-mediated perturbations |
| IVR | 0.5 mg/day | 0.5 mg/day | Affects estrogen metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:12492412 | IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Decreased weights of vagina | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:12535155 | IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Changes in Anteroventral periventricular Nucleus (AVPV) volume | Neurological endocrine-mediated perturbations |
| IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.004 mg/kg/day | 0.004 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:12547330 | IVR | 20 mg/kg | 20 mg/kg | Affects uterine function | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Affects uterine function | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Affects uterine function | Reproductive endocrine-mediated perturbations | |
| PMID:12573901 | IVR | 0.02 mg/kg | 0.02 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:12631470 | IVR | 0.1 mg/L | 0.1 mg/L | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 0.1 mg/L | 0.1 mg/L | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:12709020 | IVR | 25 mg/kg | 25 mg/kg | Changes in T-cell populations | Immunological endocrine-mediated perturbations |
| PMID:12865045 | IVR | 25 mg/kg/day | 25 mg/kg/day | Affects superoxide dismutase (SOD) levels | Hepatic endocrine-mediated perturbations |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects superoxide dismutase (SOD) levels | Hepatic endocrine-mediated perturbations | |
| PMID:12963004 | IVR | 5 - 1250 mg/kg/day | 5 - 1250 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVR | 5 - 1250 mg/kg/day | 5 - 1250 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 - 1250 mg/kg/day | 5 - 1250 mg/kg/day | Oxidative stress in uterus | Reproductive endocrine-mediated perturbations | |
| PMID:14654251 | IVR | 200 mg/kg/day | 200 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:14664715 | IVR | 0.3 mg/kg | 0.3 mg/kg | Affects expression of thyroid receptor (TR) | Metabolic endocrine-mediated perturbations |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| PMID:14689164 | IVR | 50 mg/kg | - | No significant effects observed | - |
| IVR | 5 mg/kg | - | No significant effects observed | - | |
| IVR | 200 mg/kg | 200 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:14692339 | IVR | 0.00001 M | 0.00001 M | Changes in thymus gland morphology | Immunological endocrine-mediated perturbations |
| IVR | 0.00001 M | 0.00001 M | Alterations in splenocytes population | Immunological endocrine-mediated perturbations | |
| PMID:14709801 | IVTH | 0.00000001 - 0.0001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:14746872 | IVR | 2 mg/kg | 2 mg/kg | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations |
| IVR | 500 mg/kg | 500 mg/kg | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations | |
| IVR | 2000 mg/kg | 2000 mg/kg | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations | |
| PMID:14749093 | IVR | 10 mg/L | 10 mg/L | Increased levels of Corticotropin-releasing hormone (CRH) | Neurological endocrine-mediated perturbations |
| PMID:14763995 | IVR | 40 mg/kg | 40 mg/kg | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| PMID:14967906 | IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects embryonic development | Developmental endocrine-mediated perturbations |
| PMID:14967926 | IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects skeletal development | Developmental endocrine-mediated perturbations |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects placental development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects cholesterol metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects lipid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:15051418 | IVR | 10 mg/L | 10 mg/L | Oxidative stress in testis | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/L | 5 mg/L | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Decreased brain weights | Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:15079872 | IVR | 0.00002 mg | - | No significant effects observed | - |
| IVR | 0.02 mg | 0.02 mg | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.002 mg | 0.002 mg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.02 mg | 0.02 mg | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations | |
| IVR | 0.02 mg | 0.02 mg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.0002 mg | 0.0002 mg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:15110097 | IVTH | 0.00001 - 0.001 M | 0.00001 - 0.001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:15203435 | IVR | 2000 mg/kg | 2000 mg/kg | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations |
| PMID:15219628 | IVR | 200 mg/kg/day | 200 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:15501383 | IVR | 0.001 mg | 0.001 mg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.001 mg | 0.001 mg | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg | - | No significant effects observed | - | |
| IVR | 0.6 mg | - | No significant effects observed | - | |
| IVR | 0.005 mg | 0.005 mg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg | 0.005 mg | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg | 0.1 mg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg | 0.1 mg | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| PMID:15509668 | IVR | 100 mg/kg | - | No significant effects observed | - |
| IVR | 250 mg/kg | 250 mg/kg | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| PMID:15518916 | IVR | 0.087 M | 0.087 M | Affects locomotor activity | Neurological endocrine-mediated perturbations |
| IVR | 0.087 M | 0.087 M | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.087 M | 0.087 M | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.087 M | 0.087 M | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations | |
| PMID:15548368 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects uterine development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| PMID:15620428 | IVR | 0.087 M | 0.087 M | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 0.087 M | 0.087 M | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations | |
| PMID:15635150 | IVR | 300 mg/kg/day | 300 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:15738621 | IVR | 20 mg/kg/day | 20 mg/kg/day | Affects thyroid hormone metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.00002 mg/kg/day | 0.00002 mg/kg/day | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVR | 0.00002 mg/kg/day | 0.00002 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.00002 mg/kg/day | 0.00002 mg/kg/day | Affects thyroid hormone metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects thyroid hormone metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:15866537 | IVR | 300 mg/kg | - | No significant effects observed | - |
| IVR | 30 mg/kg | - | No significant effects observed | - | |
| IVR | 3 mg/kg | - | No significant effects observed | - | |
| IVR | 10 mg/kg | - | No significant effects observed | - | |
| IVR | 1 mg/kg | - | No significant effects observed | - | |
| IVR | 100 mg/kg | 100 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects uterine function | Reproductive endocrine-mediated perturbations | |
| PMID:15867144 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:16029874 | IVTH | 0.000001 M | 0.000001 M | Affects cytokine signaling | Immunological endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| PMID:16123166 | IVR | 0.000000000001 - 0.000001 M | 0.0000000001 - 0.000001 M | Affects estrogen signaling | Reproductive endocrine-mediated perturbations |
| PMID:16284450 | IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Oxidative stress in nervous system | Neurological endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Oxidative stress in nervous system | Neurological endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00002 mg/kg/day | 0.00002 mg/kg/day | Oxidative stress in nervous system | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Oxidative stress in nervous system | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| PMID:16323634 | IVR | 50 mg/kg/day | 50 mg/kg/day | Decreased prolactin levels | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects litter size | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Decreased placental weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects litter size | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Changes in placental morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Decreased placental weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| PMID:16427766 | IVR | 0.5 mg/kg | 0.5 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Changes in Anteroventral periventricular Nucleus (AVPV) volume | Neurological endocrine-mediated perturbations | |
| PMID:16540110 | IVR | 0.002 mg/kg/day | - | No significant effects observed | - |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Accelerated onset of puberty | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:16675520 | IVR | 0.000025 mg/kg | - | No significant effects observed | - |
| IVR | 0.00025 mg/kg | 0.00025 mg/kg | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:16678967 | IVR | 0.03 - 2000 mg/kg | 0.03 - 2000 mg/kg | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations |
| PMID:16740699 | IVR | 0.01 mg/kg | 0.01 mg/kg | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Prostate hyperplasia | Reproductive endocrine-mediated perturbations | |
| PMID:16819149 | IVR | 0.0024 mg/kg/day | 0.0024 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| PMID:17010207 | IVR | 600 mg/kg | 600 mg/kg | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| PMID:17023525 | IVR | 0.00025 mg | 0.00025 mg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.00025 mg | 0.00025 mg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:17093138 | IVTH | 0.0000000001 - 0.000025 M | 0.0000000001 - 0.000025 M | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| PMID:17109964 | IVR | 0.25 mg | 0.25 mg | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:17113258 | IVR | 0.003 mg | 0.003 mg | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| PMID:17123778 | IVR | 0.025 mg/kg | - | No significant effects observed | - |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations | |
| PMID:17157476 | IVR | 0.04 mg/kg | 0.04 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:17365578 | IVR | 200 mg/kg | 200 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| IVR | 400 mg/kg | 400 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:17450229 | IVR | 0.00025 mg/kg/day | 0.00025 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations |
| PMID:17467901 | IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations |
| IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Affects acetylcholinesterase activity | Neurological endocrine-mediated perturbations | |
| IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Affects acetylcholinesterase activity | Neurological endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| PMID:17508988 | IVR | 2000 mg/kg | 2000 mg/kg | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations |
| PMID:17568585 | IVR | 0.01 mg/kg | 0.01 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:17689037 | IVR | 0.6 mg/day | 0.6 mg/day | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations |
| IVR | 0.6 mg/day | 0.6 mg/day | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.6 mg/day | 0.6 mg/day | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations | |
| IVR | 0.6 mg/day | 0.6 mg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:17804194 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Uterine hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Uterine hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| PMID:17827700 | IVR | 10 mg/L | 10 mg/L | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 10 mg/L | 10 mg/L | Changes in T-cell populations | Immunological endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| PMID:17983274 | IVTH | 0.000000001 - 0.0001 M | 0.000005 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:18007998 | IVTH | 0.000000001 M | 0.000000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000000001 M | 0.000000001 M | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| PMID:18087818 | IVR | 300 mg/L | 300 mg/L | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations |
| IVR | 300 mg/L | 300 mg/L | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVR | 15 mg/L | 15 mg/L | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVR | 15 mg/L | 15 mg/L | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| IVR | 75 mg/L | 75 mg/L | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| IVR | 75 mg/L | 75 mg/L | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| PMID:18174953 | IVTH | 0.00000001 - 0.0001 M | 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:18180321 | IVR | 0.025 mg/kg | 0.025 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:18418863 | IVR | 154 mg/kg/day | 154 mg/kg/day | Pregnancy complications | Reproductive endocrine-mediated perturbations |
| IVR | 154 mg/kg/day | 154 mg/kg/day | Affects cholesterol transport | Metabolic endocrine-mediated perturbations | |
| IVR | 154 mg/kg/day | 154 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 154 mg/kg/day | 154 mg/kg/day | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 7.1 mg/kg/day | 7.1 mg/kg/day | Affects cholesterol transport | Metabolic endocrine-mediated perturbations | |
| IVR | 7.1 mg/kg/day | 7.1 mg/kg/day | Pregnancy complications | Reproductive endocrine-mediated perturbations | |
| IVR | 7.1 mg/kg/day | 7.1 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 7.1 mg/kg/day | 7.1 mg/kg/day | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| PMID:18634814 | IVTH | 0.00008 M | 0.00008 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:18640724 | IVTH | 0.00000001 - 0.00001 M | 0.00000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:18653720 | IVR | 0.05 mg/kg | 0.05 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg | 20 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| PMID:18804091 | IVR | 0.02 mg/kg | 0.02 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| PMID:18839522 | IVR | 200 mg/kg | 200 mg/kg | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 200 mg/kg | 200 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 400 mg/kg | 400 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 600 mg/kg | 600 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:18854640 | IVTH | 0.000000001 - 0.00001 M | 0.0000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:19079714 | IVTH | 0.0000000001 - 0.000000001 M | 0.0000000001 - 0.000000001 M | Lead to obesity | Metabolic endocrine-mediated perturbations |
| PMID:19106226 | IVR | 0.1 mg/kg | 0.1 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:19145065 | IVR | 100 mg/kg | - | No significant effects observed | - |
| IVR | 10 mg/kg | - | No significant effects observed | - | |
| IVR | 600 mg/kg | 600 mg/kg | Increase in Growth Hormone (GH) levels | Metabolic endocrine-mediated perturbations | |
| PMID:19193734 | IVR | 0.48 mg/kg | 0.48 mg/kg | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations |
| IVR | 0.48 mg/kg | 0.48 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.48 mg/kg | 0.48 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.48 mg/kg | 0.48 mg/kg | Induce apoptosis of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.48 mg/kg | 0.48 mg/kg | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.16 mg/kg | 0.16 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.96 mg/kg | 0.96 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.96 mg/kg | 0.96 mg/kg | Induce apoptosis of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.96 mg/kg | 0.96 mg/kg | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| PMID:19371625 | IVTH | 0.000002 - 0.000005 M | 0.000002 - 0.000005 M | Affects differentiation process | Developmental endocrine-mediated perturbations |
| IVTH | 0.000002 - 0.000005 M | 0.000002 - 0.000005 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000002 - 0.000005 M | 0.000002 - 0.000005 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| PMID:19379760 | IVR | 0.0012 mg/kg | 0.0012 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| PMID:19442818 | IVR | 50 mg/kg | 50 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | - | No significant effects observed | - | |
| PMID:19490990 | IVTH | 0.00005 M | 0.00005 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:19535786 | IVR | 0.05 mg/kg | 0.05 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg | 50 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| PMID:19539015 | IVTH | 0.000001 - 0.0001 M | 0.000005 - 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:19577632 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:19590677 | IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| PMID:19654912 | IVTH | 0.000000000001 - 0.00001 M | 0.000000000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:19696011 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| PMID:19782717 | IVR | 0.0012 mg | 0.0012 mg | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 0.0012 mg | 0.0012 mg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0012 mg | 0.0012 mg | Affects litter size | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0006 mg | - | No significant effects observed | - | |
| IVR | 0.01 mg | 0.01 mg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg | 0.005 mg | Affects litter size | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Affects litter size | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg | 0.005 mg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg | 0.01 mg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg | 0.005 mg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg | 0.0024 mg | Affects litter size | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg | 0.0024 mg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg | 0.0024 mg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg | 0.0024 mg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg | 0.0024 mg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:19837096 | IVR | 0.0012 mg/kg | 0.0012 mg/kg | Increased epididymal vesicles in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0012 mg/kg | 0.0012 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0012 mg/kg | 0.0012 mg/kg | Affects litter size | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0012 mg/kg | 0.0012 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0012 mg/kg | 0.0012 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0012 mg/kg | 0.0012 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0012 mg/kg | 0.0012 mg/kg | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0012 mg/kg | 0.0012 mg/kg | Increased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0012 mg/kg | 0.0012 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Increased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Increased epididymal vesicles in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0024 mg/kg | 0.0024 mg/kg | Affects litter size | Reproductive endocrine-mediated perturbations | |
| PMID:20019905 | IVR | 1 mg/L | 1 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations |
| PMID:20064783 | IVTH | 0.04 - 0.1 mg/L | 0.04 - 0.1 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations |
| IVTH | 0.04 - 0.1 mg/L | 0.04 - 0.1 mg/L | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.04 - 0.1 mg/L | 0.04 - 0.1 mg/L | Alterations in number of granulosa cells | Reproductive endocrine-mediated perturbations | |
| PMID:20169576 | IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects locomotor activity | Neurological endocrine-mediated perturbations | |
| PMID:20172022 | IVTH | 0.000001 - 0.000005 M | 0.000001 - 0.000005 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| PMID:20181937 | IVR | 5 mg/kg | 5 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| PMID:20219646 | IVR | 0.04 mg/kg | 0.04 mg/kg | Increase in cortisol levels | Neurological endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| PMID:20219716 | IVR | 0.025 mg/kg | 0.025 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:20350546 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| PMID:20413367 | IVR | 100 mg/L | 100 mg/L | Decreased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 10000 mg/L | 10000 mg/L | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10000 mg/L | 10000 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/L | 1000 mg/L | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10000 mg/L | 10000 mg/L | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/L | 1000 mg/L | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/L | 1000 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:20488778 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Causes insulin resistance | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Increased leptin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Causes insulin resistance | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| PMID:20561153 | IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Changes in medial amygdala (MePD) nucleus volume | Neurological endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Changes in medial amygdala (MePD) nucleus volume | Neurological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Changes in medial amygdala (MePD) nucleus volume | Neurological endocrine-mediated perturbations | |
| PMID:20599497 | IVR | 200 mg/kg | 200 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations |
| IVR | 300 mg/kg | 300 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:20692330 | IVR | 0.05 mg/kg/day | - | No significant effects observed | - |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:20696184 | IVR | 0.05 mg/kg | 0.05 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg | 50 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:20709143 | IVR | 0.02 mg/kg | 0.02 mg/kg | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Increased dopamine levels | Neurological endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Increased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| PMID:20739668 | IVR | 0.02 mg/kg | 0.02 mg/kg | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects ovarian function | Reproductive endocrine-mediated perturbations | |
| PMID:20813173 | IVR | 480 mg/kg | 480 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations |
| IVR | 480 mg/kg | 480 mg/kg | Abnormal proliferation of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 480 mg/kg | 480 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 160 mg/kg | 160 mg/kg | Abnormal proliferation of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 160 mg/kg | 160 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 160 mg/kg | 160 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| PMID:20815788 | IVR | 10 mg/L | 10 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/L | 10 mg/L | Increased ROS levels in sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Increased ROS levels in sperms | Reproductive endocrine-mediated perturbations | |
| PMID:20821433 | IVR | 200 mg/kg/day | 200 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:20951796 | IVR | 20 mg/kg/day | 20 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:20955774 | IVR | 1 mg/L | 1 mg/L | Affects neuronal density | Neurological endocrine-mediated perturbations |
| IVR | 1 mg/L | 1 mg/L | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:21123812 | IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:21126938 | IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Affects fertility | Reproductive endocrine-mediated perturbations |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Affects litter size | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00025 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.000025 mg/kg/day | 0.000025 mg/kg/day | Affects fertility | Reproductive endocrine-mediated perturbations | |
| PMID:21182934 | IVR | 25 mg/kg/day | 25 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 12 mg/kg/day | 12 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:21185296 | IVR | 50 mg/kg/day | - | No significant effects observed | - |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:21273127 | IVTH | 0.000005 M | - | No significant effects observed | - |
| IVTH | 0.000025 M | - | No significant effects observed | - | |
| IVTH | 0.0001 M | 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00005 M | 0.00005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:21285323 | IVR | 20 mg/kg/day | 20 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| PMID:21415097 | IVR | 0.03 mg/kg | 0.03 mg/kg | Affects androgen signaling | Reproductive endocrine-mediated perturbations |
| IVR | 0.03 mg/kg | 0.03 mg/kg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.09 mg/kg | 0.09 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:21427057 | IVTH | 0.0003 - 3 mg/L | 0.03 - 3 mg/L | Decrease in cortisol levels | Neurological endocrine-mediated perturbations |
| IVTH | 0.0003 - 3 mg/L | 0.03 - 3 mg/L | Decreased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0003 - 3 mg/L | 0.03 - 3 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:21448315 | IVR | 0.02 mg/kg | 0.02 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| PMID:21513798 | IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| PMID:21586551 | IVR | 1.25 mg/kg/day | - | No significant effects observed | - |
| IVR | 0.25 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| PMID:21636974 | IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| PMID:21709224 | IVR | 50 mg/kg | 50 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations |
| PMID:21761357 | IVTH | 0.000000025 - 0.00025 M | 0.0000025 - 0.00025 M | Affects embryonic development | Developmental endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| PMID:21763338 | IVR | 0.05 mg/kg | 0.05 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| PMID:21771643 | IVTH | 0.0000000000001 - 0.000000001 M | 0.00001 M | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| PMID:21787652 | IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects locomotor activity | Neurological endocrine-mediated perturbations |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| PMID:21787673 | IVR | 0.05 mg/kg | 0.05 mg/kg | Causes masculinized behavior | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:21795248 | IVTH | 0.000001 - 0.00003 M | 0.000001 - 0.00003 M | Affects survival of live fetus | Reproductive endocrine-mediated perturbations |
| PMID:21826169 | IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:21827818 | IVR | 0.0024 mg/day | 0.0024 mg/day | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0024 mg/day | 0.0024 mg/day | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| PMID:21840368 | IVR | 10 mg/kg | 10 mg/kg | Affects superoxide dismutase (SOD) levels | Hepatic endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:21925253 | IVTH | 0.00000001 - 0.0001 M | 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:21988766 | IVR | 0.025 mg/L | 0.025 mg/L | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 0.025 mg/L | 0.025 mg/L | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/L | 0.25 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.25 mg/L | 0.25 mg/L | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/L | 0.0025 mg/L | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/L | 0.0025 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 2.5 mg/L | 2.5 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 2.5 mg/L | 2.5 mg/L | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:22004261 | IVR | 0.04 mg/kg | 0.04 mg/kg | Abnormal neuronal distribution | Neurological endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| PMID:22121209 | IVTH | 0.00003 M | 0.00003 M | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 0.00003 M | 0.00003 M | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| PMID:22142692 | IVR | 0.05 mg/kg | 0.05 mg/kg | Reduced insulin levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg | 0.0005 mg/kg | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg | 0.0005 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg | 0.0005 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg | 0.0005 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000005 mg/kg | 0.000005 mg/kg | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.000005 mg/kg | 0.000005 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000005 mg/kg | 0.000005 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000005 mg/kg | 0.000005 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| PMID:22201988 | IVR | 1 mg/kg/day | 1 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:22240090 | IVR | 64 mg/kg/day | 64 mg/kg/day | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVR | 0.16 mg/kg/day | 0.16 mg/kg/day | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| IVR | 16 mg/kg/day | 16 mg/kg/day | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:22263531 | IVR | 5 mg/kg | 5 mg/kg | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg | 20 mg/kg | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Increase in the number of abnormal sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Increase in the number of abnormal sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:22285353 | IVR | 200 mg/kg | 200 mg/kg | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 200 mg/kg | 200 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Increased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| PMID:22307313 | IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:22327052 | IVTH | 0.000005 - 0.0001 M | 0.000005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:22384422 | IVR | 100 mg/kg | 100 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:22403704 | IVTH | 0.00001 M | 0.00001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:22414680 | IVTH | 0.00000000000001 - 0.00000001 M | 0.0000001 M | Affects estrogen metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:22426297 | IVR | 0.2 mg/kg | 0.2 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Hyperplasia in adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| PMID:22470480 | IVR | 0.1 mg/kg | 0.1 mg/kg | Affects insulin signaling | Metabolic endocrine-mediated perturbations |
| PMID:22484357 | IVR | 0.1 mg/kg | - | No significant effects observed | - |
| IVR | 10 mg/kg | 10 mg/kg | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:22531466 | IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:22549810 | IVTH | 0.000000000001 - 0.00001 M | 0.000000001 - 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:22564983 | IVTH | 0.000001 - 0.00005 M | 0.000025 - 0.00005 M | Increased levels of Corticotropin-releasing hormone (CRH) | Neurological endocrine-mediated perturbations |
| PMID:22576693 | IVTH | 0.000001 - 0.00001 M | 0.000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:22662114 | IVTH | 0.000008 M | - | No significant effects observed | - |
| IVTH | 0.00000008 M | - | No significant effects observed | - | |
| IVTH | 0.00008 M | 0.00008 M | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| PMID:22687993 | IVR | 50 mg/kg/day | 50 mg/kg/day | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Alterations in number of sertoli cells | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Alterations in number of sertoli cells | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:22707478 | IVR | 5 mg/kg/day | 5 mg/kg/day | Pregnancy complications | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:22730197 | IVR | 0.4 mg/kg | 0.4 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Epigenomic alterations in sperm | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| PMID:22760093 | IVR | 0.00025 mg/kg | 0.00025 mg/kg | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations |
| IVR | 0.00025 mg/kg | 0.00025 mg/kg | Increased dopamine levels | Neurological endocrine-mediated perturbations | |
| PMID:22842222 | IVR | 10000 mg/L | 10000 mg/L | Causes masculinized behavior | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 1000 mg/L | 1000 mg/L | Causes masculinized behavior | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10000 mg/L | 10000 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 10000 mg/L | 10000 mg/L | Increase in Growth Hormone (GH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1000 mg/L | 1000 mg/L | Increase in Growth Hormone (GH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1000 mg/L | 1000 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:22875908 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:22951085 | IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:23142537 | IVTH | 0.01 mg/L | 0.01 mg/L | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVTH | 0.01 mg/L | 0.01 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 1 mg/L | 1 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 1 mg/L | 1 mg/L | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:23142789 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects calcium transport | Metabolic endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects calcium signaling | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects calcium signaling | Metabolic endocrine-mediated perturbations | |
| PMID:23160314 | IVR | 300 mg/L | 300 mg/L | Elevated glucose levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.03 mg/L | 0.03 mg/L | Accelerated onset of puberty | Reproductive endocrine-mediated perturbations | |
| IVR | 0.03 mg/L | 0.03 mg/L | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 300 mg/L | 300 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.03 mg/L | 0.03 mg/L | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 300 mg/L | 300 mg/L | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/L | 3 mg/L | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 3 mg/L | 3 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/L | 3 mg/L | Accelerated onset of puberty | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/L | 3 mg/L | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/L | 3 mg/L | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/L | 0.3 mg/L | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 30 mg/L | 30 mg/L | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/L | 30 mg/L | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/L | 30 mg/L | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:23229410 | IVTH | 0.0000000001 - 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.0000000001 - 0.00001 M | 0.0000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:23284716 | IVTH | 0.000000000001 - 0.00001 M | 0.00000001 - 0.00001 M | Abnormal development of gonads in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000000001 - 0.00001 M | 0.00000001 - 0.00001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:23372685 | IVTH | 0.000005 - 0.00014 M | 0.00001 M | Beta cell dysfunction | Metabolic endocrine-mediated perturbations |
| PMID:23376180 | IVR | 200 mg/kg/day | 200 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Affects glycogen metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Affects insulin signaling | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects glycogen metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:23405200 | IVR | 50 mg/kg | 50 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations |
| PMID:23457122 | IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:23490186 | IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| PMID:23496298 | IVR | 100 mg/L | 100 mg/L | Induce apoptosis of beta cells | Metabolic endocrine-mediated perturbations |
| IVR | 1 mg/L | 1 mg/L | Occurrence of Insulitis | Immunological endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Induce apoptosis of beta cells | Metabolic endocrine-mediated perturbations | |
| PMID:23545179 | IVR | 200 mg/kg/day | 200 mg/kg/day | Increased levels of Corticotropin-releasing hormone (CRH) | Neurological endocrine-mediated perturbations |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Increased levels of Corticotropin-releasing hormone (CRH) | Neurological endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations | |
| PMID:23593014 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects embryonic development | Developmental endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects implantation | Reproductive endocrine-mediated perturbations | |
| PMID:23620208 | IVR | 0.3 mg/kg | 0.3 mg/kg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:23664861 | IVR | 100 mg/kg/day | 100 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| PMID:23672405 | IVTH | 0.000000001 - 0.000001 M | 0.00000001 - 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000000001 - 0.000001 M | 0.00000001 - 0.000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000001 - 0.000001 M | 0.0000001 - 0.000001 M | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:23675523 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Causes insulin resistance | Metabolic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Beta cell dysfunction | Metabolic endocrine-mediated perturbations | |
| PMID:23704952 | IVR | 0.00025 mg/kg/day | 0.00025 mg/kg/day | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.00025 mg/kg/day | 0.00025 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.00025 mg/kg/day | 0.00025 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:23716699 | IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:23748860 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects liver function | Hepatic endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects glycogen metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Causes insulin resistance | Metabolic endocrine-mediated perturbations | |
| PMID:23770294 | IVR | 5 mg/kg | 5 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:23788033 | IVR | 0.002 mg/kg | - | No significant effects observed | - |
| IVR | 0.02 mg/kg | - | No significant effects observed | - | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:23810794 | IVTH | 0.00001 M | 0.00001 M | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00001 M | 0.00001 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:23915859 | IVTH | 0.0000000001 - 0.0001 M | 0.00000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.0000000001 - 0.0001 M | 0.00000001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| IVTH | 0.0000000001 - 0.0001 M | 0.00000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:23926155 | IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:24147964 | IVR | 0.08 mg/kg | 0.08 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects peneration rate of sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| PMID:24189131 | IVR | 10 mg/L | 10 mg/L | Changes in T-cell populations | Immunological endocrine-mediated perturbations |
| IVR | 10 mg/L | 10 mg/L | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Occurrence of Insulitis | Immunological endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Changes in B-cell populations | Immunological endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Alterations in splenocytes population | Immunological endocrine-mediated perturbations | |
| PMID:24257414 | IVR | 0.025 mg/kg | 0.025 mg/kg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| PMID:24269606 | IVR | 0.005 mg/kg | 0.005 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| PMID:24271643 | IVR | 0.003 mg/kg/day | 0.003 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.003 mg/kg/day | 0.003 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.003 mg/kg/day | 0.003 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.003 mg/kg/day | 0.003 mg/kg/day | Alters hypothalamic-pituitary-testicular axis | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:24305612 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Erectile dysfunction | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Erectile dysfunction | Reproductive endocrine-mediated perturbations | |
| PMID:24308608 | IVTH | 0.000001 M | 0.000001 M | Affects cytokine signaling | Immunological endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:24323913 | IVR | 0.04 mg/kg | 0.04 mg/kg | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Hyperplasia of zona fasciculata in adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| PMID:24333847 | IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| PMID:24352099 | IVR | 50 mg/kg | 50 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:24418828 | IVTH | 0.000001 - 0.00005 M | 0.000025 - 0.00005 M | Lead to obesity | Metabolic endocrine-mediated perturbations |
| PMID:24440629 | IVR | 0.004 mg/kg | 0.004 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | - | No significant effects observed | - | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| PMID:24533973 | IVR | 0.025 mg/kg | 0.025 mg/kg | Induce cancer metastasis | Endocrine-mediated cancer |
| IVTH | 0.00000001 M | 0.00000001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| PMID:24563381 | IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decreased Dehydroepiandrosterone (DHEA) levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Increased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| PMID:24566421 | IVR | 0.025 mg/kg/day | - | No significant effects observed | - |
| IVR | 0.064 mg/kg/day | 0.064 mg/kg/day | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:24586459 | IVTH | 0.00000001 - 0.0001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00000001 - 0.0001 M | 0.00001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.0001 M | 0.00001 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:24632125 | IVTH | 0.00000000001 - 0.00000001 M | 0.00000000001 - 0.00000001 M | Affects endometrial angiogenesis | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000000001 - 0.00000001 M | 0.00000000001 - 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:24648961 | IVR | 0.00000001 M | 0.00000001 M | Affects sertoli cells function | Reproductive endocrine-mediated perturbations |
| IVR | 0.00000001 M | 0.00000001 M | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00000001 M | 0.00000001 M | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0000001 M | 0.0000001 M | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0000001 M | 0.0000001 M | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0000001 M | 0.0000001 M | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000001 M | 0.000001 M | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000001 M | 0.000001 M | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000001 M | 0.000001 M | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| PMID:24705360 | IVR | 0.001 mg/L | 0.001 mg/L | Causes insulin resistance | Metabolic endocrine-mediated perturbations |
| IVR | 0.001 mg/L | 0.001 mg/L | Affects glucose metabolism in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.001 mg/L | 0.001 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/L | 0.01 mg/L | Causes insulin resistance | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/L | 0.01 mg/L | Affects glucose metabolism in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/L | 0.01 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:24726836 | IVR | 0.003 - 3 mg/kg/day | 0.003 - 3 mg/kg/day | Decreased liver weights | Hepatic endocrine-mediated perturbations |
| IVR | 0.003 - 3 mg/kg/day | 0.003 - 3 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:24752506 | IVR | 0.4 mmol/kg/day | 0.4 mmol/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.4 mmol/kg/day | 0.4 mmol/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.8 mmol/kg/day | 0.8 mmol/kg/day | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.8 mmol/kg/day | 0.8 mmol/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:24752507 | IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0025 mg/kg/day | - | No significant effects observed | - | |
| IVR | 2.7 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.26 mg/kg/day | - | No significant effects observed | - | |
| PMID:24857958 | IVR | 0.002 mg/kg | 0.002 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Increased levels of Corticotropin-releasing hormone (CRH) | Neurological endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Increased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:24959901 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:24975924 | IVR | 0.04 mg/kg | 0.04 mg/kg | Abnormal neuronal distribution | Neurological endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:25047013 | IVTH | 0.00005 M | 0.00005 M | Increased triglycerides level | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00005 M | 0.00005 M | Affects lipid metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:25051448 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Changes in Anteroventral periventricular Nucleus (AVPV) volume | Neurological endocrine-mediated perturbations | |
| PMID:25074486 | IVR | 0.1 mg/L | 0.1 mg/L | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/L | 0.1 mg/L | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:25111128 | IVTH | 0.000000000000001 M | 0.000000000000001 M | Increased triglycerides level | Metabolic endocrine-mediated perturbations |
| IVTH | 0.000000000000001 M | 0.000000000000001 M | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000000000001 M | 0.000000000001 M | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000000000001 M | 0.000000000001 M | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000000000001 M | 0.000000000001 M | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:25112706 | IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | - | No significant effects observed | - | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:25130739 | IVTH | 0.000000000001 - 0.0001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:25143472 | IVTH | 0.0000000001 - 10 M | 0.00000001 - 1 M | Lead to obesity | Metabolic endocrine-mediated perturbations |
| PMID:25168180 | IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Affects cholesterol metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects cholesterol biosynthesis | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects cholesterol metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects cholesterol biosynthesis | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects cholesterol biosynthesis | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects cholesterol metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| PMID:25330104 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects neuronal density | Neurological endocrine-mediated perturbations |
| PMID:25381574 | IVR | 0.004 mg/kg | 0.004 mg/kg | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 0.004 mg/kg | 0.004 mg/kg | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| PMID:25421748 | IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations |
| IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg/day | 0.4 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| PMID:25434757 | IVR | 0.003 mg/kg/day | 0.003 mg/kg/day | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations |
| IVR | 0.003 mg/kg/day | 0.003 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.003 mg/kg/day | 0.003 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| PMID:25448896 | IVR | 50 mg/kg/day | 50 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Induce apoptosis of sertoli cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| PMID:25461564 | IVR | 200 mg/kg/day | 200 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Increase in the number of abnormal sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increase in the number of abnormal sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| PMID:25461906 | IVR | 10 - 500 mg/kg | 20 - 500 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations |
| PMID:25474107 | IVR | 50 mg/kg | 50 mg/kg | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVR | 50 mg/kg | 50 mg/kg | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | - | No significant effects observed | - | |
| IVR | 100 mg/kg | 100 mg/kg | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| PMID:25569322 | IVR | 0.0005 mg/kg | 0.0005 mg/kg | Increased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg | 0.0005 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg | 0.0005 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg | 0.0005 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg | 0.0005 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Increased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:25594248 | IVTH | 0.00000005 M | 0.00000005 M | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations |
| PMID:25603046 | IVR | 50 mg/kg | 50 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations |
| PMID:25612011 | IVR | 0.002 - 0.05 mg/kg | 0.002 - 0.05 mg/kg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.002 - 0.05 mg/kg | 0.002 - 0.05 mg/kg | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:25615633 | IVR | 0.0005 mg | 0.0005 mg | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 0.0005 mg | 0.0005 mg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00002 mg | 0.00002 mg | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.00002 mg | 0.00002 mg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:25619500 | IVTH | 0.0005 - 0.05 mg/L | 0.0005 - 0.05 mg/L | Affects glucose metabolism | Metabolic endocrine-mediated perturbations |
| PMID:25690688 | IVTH | 0.000001 M | 0.000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| PMID:25706302 | IVTH | 0.000000001 - 0.00001 M | 0.00000001 - 0.00001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| PMID:25725483 | IVR | 0.025 mg/kg | 0.025 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVTH | 0.00000001 M | 0.00000001 M | Affects developmental process | Developmental endocrine-mediated perturbations | |
| PMID:25748669 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations |
| PMID:25797437 | IVTH | 0.000000001 - 0.000001 M | 0.000000001 - 0.000001 M | Cervical carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| PMID:25830705 | IVR | 0.01 mg/kg | 0.01 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| PMID:25853433 | IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:25878060 | IVTH | 0.000000001 - 0.0000001 M | 0.000000001 - 0.0000001 M | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations |
| PMID:25903087 | IVR | 25 mg/kg | 25 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:25938496 | IVTH | 0.000000001 - 0.00001 M | 0.00000001 - 0.00001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| PMID:25972359 | IVR | 0.05 mg/kg | 0.05 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| PMID:26021997 | IVTH | 0.000000000001 M | 0.000000000001 M | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000000001 M | 0.000000000001 M | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000000001 M | 0.000000000001 M | Changes in B-cell populations | Immunological endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Changes in B-cell populations | Immunological endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Changes in B-cell populations | Immunological endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| PMID:26027920 | IVTH | 0.000000000000001 - 0.0000001 M | 0.00000000001 - 0.000000001 M | Affects placental development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:26063408 | IVR | 0.5 mg/kg | 0.5 mg/kg | Affects glycogen metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects placental development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Changes in placental morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| PMID:26098999 | IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Prostate hyperplasia | Reproductive endocrine-mediated perturbations |
| PMID:26146954 | IVR | 25 mg/kg | 25 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVR | 25 mg/kg | 25 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| PMID:26186136 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:26222054 | IVTH | 0.00000001 M | 0.00000001 M | Affects embryonic development | Developmental endocrine-mediated perturbations |
| IVTH | 0.00000001 M | 0.00000001 M | Affects prostate development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Affects prostate development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:26250451 | IVR | 0.9 mg/kg/day | 0.9 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 0.9 mg/kg/day | 0.9 mg/kg/day | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.9 mg/kg/day | 0.9 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.9 mg/kg/day | 0.9 mg/kg/day | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.9 mg/kg/day | 0.9 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg/day | 0.3 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg/day | 0.3 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg/day | 0.3 mg/kg/day | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| PMID:26276081 | IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Beta cell dysfunction | Metabolic endocrine-mediated perturbations | |
| PMID:26307436 | IVR | 0.03 - 300 mg/L | 0.03 - 300 mg/L | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 0.03 - 300 mg/L | 0.03 - 300 mg/L | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| PMID:26363213 | IVTH | 0.000000001 - 0.0000001 M | 0.000000001 - 0.00000001 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVTH | 0.000000001 - 0.0000001 M | 0.000000001 - 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:26372177 | IVR | 0.025 mg/kg | 0.025 mg/kg | Affects testicular development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Affects testicular development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| PMID:26376105 | IVR | 2 mg/kg | 2 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations |
| IVR | 2 mg/kg | 2 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects uterine function | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects uterine function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| PMID:26427651 | IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations |
| PMID:26443714 | IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| PMID:26484192 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects placental development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Changes in placental morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects placental development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Changes in placental morphology | Reproductive endocrine-mediated perturbations | |
| PMID:26496021 | IVR | 15 mg | 15 mg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations |
| IVR | 30 mg | 30 mg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| PMID:26529182 | IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Changes in morphology of paraurethral glands | Reproductive endocrine-mediated perturbations |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg/day | 4 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:26604029 | IVTH | 0.00000000001 M | 0.00000000001 M | Pregnancy complications | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 M | 0.00000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| IVTH | 0.00000001 M | 0.00000001 M | Pregnancy complications | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | - | No significant effects observed | - | |
| PMID:26712468 | IVR | 4 M | 4 M | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| PMID:26746108 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:26751127 | IVTH | 0.00001 - 0.0005 M | 0.000001 - 0.00007 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00001 - 0.0005 M | 0.000001 - 0.00007 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0005 M | 0.000001 - 0.00007 M | Decreased progestagens levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0005 M | 0.000001 - 0.00007 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:26779933 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects insulin signaling | Metabolic endocrine-mediated perturbations |
| PMID:26812801 | IVR | 25 mg/kg | 25 mg/kg | Beta cell dysfunction | Metabolic endocrine-mediated perturbations |
| PMID:26823751 | IVTH | 0.00000001 - 0.001 M | 0.00000001 - 0.0001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00000001 - 0.001 M | 0.00000001 - 0.0001 M | Induce tumor progression | Endocrine-mediated cancer | |
| PMID:26827910 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| PMID:26828634 | IVR | 0.004 mg/kg/day | 0.004 mg/kg/day | Affects neuronal density | Neurological endocrine-mediated perturbations |
| IVR | 0.4 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| PMID:26863571 | IVR | 5 mg/kg | 5 mg/kg | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Abnormal proliferation of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Abnormal proliferation of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Abnormal proliferation of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:26869994 | IVR | 0.04 mg/kg | 0.04 mg/kg | Abnormal neuronal distribution | Neurological endocrine-mediated perturbations |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:26898831 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects Wnt signaling pathway | Developmental endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:26911702 | IVR | 5 mg/kg | 5 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| PMID:26922907 | IVTH | 0.00001 M | 0.00001 M | Affects blood-testis barrier (BTB) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| PMID:26923231 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects insulin signaling | Metabolic endocrine-mediated perturbations | |
| PMID:26950200 | IVR | 0.000025 mg/kg/day | 0.000025 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.000025 mg/kg/day | 0.000025 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000005 mg/kg/day | 0.000005 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.000005 mg/kg/day | 0.000005 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| PMID:26970683 | IVR | 5 mg/kg/day | 5 mg/kg/day | Affects survival of germ cells | Reproductive endocrine-mediated perturbations |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:26975478 | IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:27017381 | IVR | 25 mg/kg | 25 mg/kg | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations |
| IVR | 25 mg/kg | 25 mg/kg | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| PMID:27022676 | IVR | 0.005 - 5 mg/kg/day | 0.005 - 5 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| PMID:27036933 | IVTH | 0.0000001 M | - | No significant effects observed | - |
| IVTH | 0.000000001 M | 0.000000001 M | Affects xenobiotic transport | Metabolic endocrine-mediated perturbations | |
| PMID:27038254 | IVTH | 0.000000001 - 0.0000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:27088260 | IVR | 0.025 - 50 mg/kg/day | 0.025 mg/kg/day | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations |
| IVR | 0.025 - 50 mg/kg/day | 0.025 mg/kg/day | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:27089241 | IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Causes masculinized behavior | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.25 mg/kg/day | - | No significant effects observed | - | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| PMID:27102938 | IVR | 50 mg/kg | - | No significant effects observed | - |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:27103539 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:27125968 | IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Affects peneration rate of sperms | Reproductive endocrine-mediated perturbations |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects peneration rate of sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| PMID:27174447 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects blood-testis barrier (BTB) | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:27182052 | IVR | 0.025 mg/kg | 0.025 mg/kg | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 M | 0.0000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| PMID:27296223 | IVR | 100 mg/kg | 100 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| PMID:27312807 | IVR | 5 mg/kg/day | 5 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations |
| PMID:27334623 | IVR | 0.00005 mg/kg | 0.00005 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:27373758 | IVR | 2 mg/L | 2 mg/L | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:27384531 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects fertility | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| PMID:27539358 | IVR | 2 mg/kg | 2 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/kg | 2 mg/kg | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| PMID:27571134 | IVR | 0.0025 - 25 mg/kg/day | 0.0025 - 25 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:27573348 | IVR | 300 mg/kg | 300 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations |
| IVR | 300 mg/kg | 300 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 300 mg/kg | 300 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:27592323 | IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Affects skeletal development | Developmental endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| PMID:27631330 | IVR | 100 mg/L | 100 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 100 mg/L | 100 mg/L | Cognitive impairment | Neurological endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Cognitive impairment | Neurological endocrine-mediated perturbations | |
| PMID:27658648 | IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| PMID:27684650 | IVTH | 0.000000001 - 0.00000001 M | 0.000000001 - 0.00000001 M | Affects developmental process | Developmental endocrine-mediated perturbations |
| PMID:27841950 | IVR | 5 mg/kg | 5 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| PMID:27998958 | IVTH | 0.00000000001 - 0.0000001 M | 0.00000000001 - 0.0000001 M | Induce tumor progression | Endocrine-mediated cancer |
| PMID:28067316 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations |
| PMID:28078498 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations | |
| PMID:28089772 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations |
| PMID:28153594 | IVR | 400 mg/kg/day | 400 mg/kg/day | Affects insulin signaling | Metabolic endocrine-mediated perturbations |
| IVR | 10 mg/kg/day | - | No significant effects observed | - | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects insulin signaling | Metabolic endocrine-mediated perturbations | |
| PMID:28196854 | IVR | 50 mg/kg | 50 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations |
| PMID:28216266 | IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:28238728 | IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00000001 M | 0.00000001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| IVTH | 0.0001 M | 0.0001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0001 M | 0.0001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| PMID:28244015 | IVTH | 0.00000001 M | 0.00000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| PMID:28279065 | IVR | 300 mg/L | 300 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations |
| IVR | 15 mg/L | 15 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 75 mg/L | 75 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| PMID:28323920 | IVR | 0.02 mg/L | 0.02 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations |
| IVR | 0.02 mg/L | 0.02 mg/L | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| PMID:28384430 | IVR | 0.02 mg/kg | 0.02 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| PMID:28426875 | IVTH | 0.000000001 - 0.00001 M | 0.000000001 M | Affects differentiation process | Developmental endocrine-mediated perturbations |
| IVTH | 0.000000001 - 0.00001 M | 0.000000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:28482050 | IVTH | 0.000000001 - 0.00001 M | 0.000000001 M | Abnormal development of gonads in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000001 - 0.00001 M | 0.000000001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:28496034 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| PMID:28549143 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects bile acid pathway | Metabolic endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects bile acid pathway | Metabolic endocrine-mediated perturbations | |
| PMID:28576649 | IVR | 4 mg/kg | 4 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 4 mg/kg | 4 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| PMID:28578073 | IVTH | 0.00002 M | - | No significant effects observed | - |
| IVTH | 0.00005 M | - | No significant effects observed | - | |
| IVTH | 0.0001 M | 0.0001 M | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:28628672 | IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:28641706 | IVR | 5 mg/kg | 5 mg/kg | Increased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:28657538 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:28676390 | IVR | 10 mg/kg | 10 mg/kg | Affects testicular morphology | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 50000 mg/kg | 50000 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:28709031 | IVTH | 0.0000001 - 0.0001 M | 0.0000001 - 0.0001 M | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVTH | 0.0000001 - 0.0001 M | 0.0000001 - 0.0001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:28729173 | IVTH | 0.01 mg/L | - | No significant effects observed | - |
| IVTH | 0.5 mg/L | - | No significant effects observed | - | |
| IVTH | 0.001 mg/L | - | No significant effects observed | - | |
| IVTH | 20 mg/L | 20 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 20 mg/L | 20 mg/L | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVTH | 20 mg/L | 20 mg/L | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVTH | 20 mg/L | 20 mg/L | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVTH | 10 mg/L | 10 mg/L | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVTH | 10 mg/L | 10 mg/L | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVTH | 10 mg/L | 10 mg/L | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| PMID:28733891 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Changes in T-cell populations | Immunological endocrine-mediated perturbations | |
| PMID:28736254 | IVTH | 0.00000001 - 0.00001 M | 0.000001 - 0.00001 M | Changes in placental morphology | Reproductive endocrine-mediated perturbations |
| PMID:28739533 | IVR | 400 mg/kg/day | 400 mg/kg/day | Affects insulin signaling | Metabolic endocrine-mediated perturbations |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Causes insulin resistance | Metabolic endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects insulin signaling | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Causes insulin resistance | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects insulin signaling | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Causes insulin resistance | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| PMID:28772150 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects skeletal development | Developmental endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| PMID:28808208 | IVTH | 0.0000001 - 0.00001 M | 0.000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.0000001 - 0.00001 M | 0.000001 - 0.00001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:28857484 | IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects epididymis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects epididymis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:28874690 | IVR | 0.25 mg/kg | 0.25 mg/kg | Induce tumor progression | Endocrine-mediated cancer |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:28890130 | IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Changes in Anteroventral periventricular Nucleus (AVPV) volume | Neurological endocrine-mediated perturbations |
| IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Changes in medial amygdala (MePD) nucleus volume | Neurological endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Changes in Anteroventral periventricular Nucleus (AVPV) volume | Neurological endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Changes in medial amygdala (MePD) nucleus volume | Neurological endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Changes in medial amygdala (MePD) nucleus volume | Neurological endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Changes in Anteroventral periventricular Nucleus (AVPV) volume | Neurological endocrine-mediated perturbations | |
| PMID:28938483 | IVR | 0.025 mg/kg | 0.025 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:28951153 | IVTH | 20 mg/L | 20 mg/L | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations |
| IVTH | 20 mg/L | 20 mg/L | Induce apoptosis of granulosa cells | Reproductive endocrine-mediated perturbations | |
| PMID:28962342 | IVR | 1 mg/L | 1 mg/L | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations |
| IVR | 1 mg/L | 1 mg/L | Accelerated onset of diabetes | Metabolic endocrine-mediated perturbations | |
| PMID:28964603 | IVTH | 0.000001 M | 0.000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| PMID:28970132 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects folliculogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects steroidogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects folliculogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects steroidogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:29031578 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:29092056 | IVR | 0.05 mg/kg/day | - | No significant effects observed | - |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Decreased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects pituitary gland function | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.00005 mg/kg/day | 0.00005 mg/kg/day | Affects pituitary gland function | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:29097150 | IVR | 0.0025 - 25 mg/kg/day | 0.025 - 25 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:29103408 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects embryonic development | Developmental endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| PMID:29161229 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Beta cell dysfunction | Metabolic endocrine-mediated perturbations |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Beta cell dysfunction | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| PMID:29165653 | IVR | 0.0005 mg/kg | 0.0005 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| PMID:29190921 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects ovulation | Reproductive endocrine-mediated perturbations |
| PMID:29220483 | IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| PMID:29228121 | IVTH | 0.000000001 - 0.000001 M | 0.000000001 - 0.000001 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVTH | 0.000000001 - 0.000001 M | 0.000000001 - 0.000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:29250801 | IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Affects estrogen metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:29269058 | IVR | 5 mg/kg | 5 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| PMID:29280353 | IVR | 0.025 mg/kg | 0.025 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | 0.0025 mg/kg | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| PMID:29305326 | IVR | 100 mg/L | 100 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 1000 mg/L | 1000 mg/L | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10000 mg/L | 10000 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| PMID:29310425 | IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| PMID:29323181 | IVR | 0.03 mg/kg | 0.03 mg/kg | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 0.03 mg/kg | 0.03 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.03 mg/kg | 0.03 mg/kg | Increased estrogen/androgen ratio | Reproductive endocrine-mediated perturbations | |
| IVR | 0.09 mg/kg | 0.09 mg/kg | Increase in estradiol/testosterone ratio | Reproductive endocrine-mediated perturbations | |
| IVR | 0.09 mg/kg | 0.09 mg/kg | Increased estrogen/androgen ratio | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increased estrogen/androgen ratio | Reproductive endocrine-mediated perturbations | |
| IVR | 0.09 mg/kg | 0.09 mg/kg | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 0.09 mg/kg | 0.09 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:29367495 | IVR | 10 mg/kg | 10 mg/kg | Exhibit sexual dimorphism | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:29383186 | IVTH | 0.00001 M | 0.00001 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0001 M | 0.0001 M | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0001 M | 0.0001 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00005 M | 0.00005 M | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| IVTH | 0.00005 M | 0.00005 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00005 M | 0.00005 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00005 M | 0.00005 M | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| PMID:29407803 | IVR | 50 mg/kg | 50 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg | 50 mg/kg | Delayed puberty | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | - | No significant effects observed | - | |
| IVR | 5 mg/kg | 5 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Delayed puberty | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:29420593 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:29440646 | IVR | 0.1 mg/L | 0.1 mg/L | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| PMID:29476947 | IVR | 5 mg/L | 5 mg/L | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 5 mg/L | 5 mg/L | Affects neuronal differentiation in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:29596923 | IVR | 25 mg/kg/day | 25 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.0025 mg/kg/day | - | No significant effects observed | - | |
| IVR | 2.5 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.25 mg/kg/day | - | No significant effects observed | - | |
| PMID:29605410 | IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.01 mg/L | 0.01 mg/L | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.1 mg/L | 0.1 mg/L | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVTH | 1 mg/L | 1 mg/L | Affects implantation | Reproductive endocrine-mediated perturbations | |
| PMID:29633606 | IVR | 0.02 mg/kg | 0.02 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| PMID:29715189 | IVR | 0.1 mg/kg | 0.1 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Beta cell dysfunction | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Oxidative stress in pancreas | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:29715755 | IVR | 500 mg/kg | 500 mg/kg | Affects skeletal development | Developmental endocrine-mediated perturbations |
| IVR | 500 mg/kg | 500 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Decreased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| PMID:29718440 | IVTH | 0.00000001 M | 0.00000001 M | Affects Wnt signaling pathway | Developmental endocrine-mediated perturbations |
| IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00000001 M | 0.00000001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| IVTH | 0.00000001 M | 0.00000001 M | Ovarian carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Ovarian carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Affects Wnt signaling pathway | Developmental endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0000001 M | 0.0000001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| PMID:29721103 | IVTH | 0.00001 M | 0.00001 M | Lead to obesity | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00005 M | 0.00005 M | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:29737898 | IVR | 0.000000000357142857142858 mmol/kg/day | - | No significant effects observed | - |
| IVR | 0.000000142857142857143 mmol/kg/day | - | No significant effects observed | - | |
| IVR | 0.00000000714285714285715 mmol/kg/day | 0.00000000714285714285715 mmol/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| PMID:29741722 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects germ cell development in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Increased testis weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Reduced sperm counts in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Affects germ cell development in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg/day | 0.02 mg/kg/day | Reduced sperm counts in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects germ cell development in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects steroidogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:29752986 | IVR | 0.000025 mg/kg/day | 0.000025 mg/kg/day | Affects folliculogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.00025 mg/kg/day | 0.00025 mg/kg/day | Affects folliculogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Abnormal estrous cycles in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Affects folliculogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:29777495 | IVR | 150 mg/kg/day | 150 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 150 mg/kg/day | 150 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 150 mg/kg/day | 150 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 150 mg/kg/day | 150 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:29843047 | IVR | 10 mg/kg/day | 10 mg/kg/day | Increased prostate weights | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:29885613 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Increased cholesterol levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects fatty acid metabolism in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects lipid metabolism in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased cholesterol levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| PMID:29907759 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects implantation | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:29935216 | IVR | 5 mg/kg | 5 mg/kg | Affects calcium signaling | Metabolic endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| PMID:29960846 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects liver function | Hepatic endocrine-mediated perturbations |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects liver function | Hepatic endocrine-mediated perturbations | |
| PMID:29964091 | IVTH | 0.00000001 mmol | 0.00000001 mmol | Affects cytokine signaling | Immunological endocrine-mediated perturbations |
| IVTH | 0.00000001 mmol | 0.00000001 mmol | Oxidative stress in uterus | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 mmol | 0.0000001 mmol | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVTH | 0.0000001 mmol | 0.0000001 mmol | Oxidative stress in uterus | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 mmol | 0.0000001 mmol | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVTH | 0.000001 mmol | 0.000001 mmol | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 mmol | 0.000001 mmol | Oxidative stress in uterus | Reproductive endocrine-mediated perturbations | |
| PMID:30001178 | IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Affects sexual behavior in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:30017639 | IVR | 300 mg/kg/day | 300 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 300 mg/kg/day | 300 mg/kg/day | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 300 mg/kg/day | 300 mg/kg/day | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 300 mg/kg/day | 300 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| PMID:30022450 | IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:30054528 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects spatial learning in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects spatial memory in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects spatial learning in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects spatial memory in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:30061528 | IVR | 100 mg/kg/day | 100 mg/kg/day | Affects implantation | Reproductive endocrine-mediated perturbations |
| PMID:30102602 | IVR | 50 mg/kg | 50 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Changes in mammary gland morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Changes in mammary gland morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:30120946 | IVR | 0.025 mg/L | 0.025 mg/L | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations |
| IVR | 0.025 mg/L | 0.025 mg/L | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/L | - | No significant effects observed | - | |
| IVR | 0.05 mg/L | 0.05 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects testicular morphology | Reproductive endocrine-mediated perturbations | |
| PMID:30121228 | IVR | 500 mg/kg/day | 500 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 50000 mg/kg/day | 50000 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50000 mg/kg/day | 50000 mg/kg/day | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| PMID:30144705 | IVTH | 0.0004 M | 0.0004 M | Affects differentiation process | Developmental endocrine-mediated perturbations |
| IVTH | 0.0000001 M | - | No significant effects observed | - | |
| IVTH | 0.00000001 M | 0.00000001 M | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| IVTH | 0.00000001 M | 0.00000001 M | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00001 M | - | No significant effects observed | - | |
| IVTH | 0.000001 M | - | No significant effects observed | - | |
| IVTH | 0.00005 M | - | No significant effects observed | - | |
| IVTH | 0.0001 M | 0.0001 M | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0002 M | 0.0002 M | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| PMID:30147835 | IVR | 10 mg/kg | 10 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Increased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| PMID:30156179 | IVR | 5 mg/L | 5 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations |
| PMID:30206973 | IVTH | 0.00001 M | 0.00001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000001 M | - | No significant effects observed | - | |
| IVTH | 0.00000001 M | 0.00000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:30219569 | IVTH | 0.0001 M | 0.0001 M | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0001 M | 0.0001 M | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:30228064 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| PMID:30264589 | IVR | 50 mg/kg | 50 mg/kg | Increased triglycerides level | Metabolic endocrine-mediated perturbations |
| PMID:30269681 | IVR | 25 mg/kg/day | 25 mg/kg/day | Oxidative stress in ovaries | Reproductive endocrine-mediated perturbations |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Decreased estrogen levels | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Affects the biochemical composition of ovary | Reproductive endocrine-mediated perturbations | |
| PMID:30275377 | IVR | 2 mg/L | 2 mg/L | Abnormal sperm morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/L | 2 mg/L | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/L | 2 mg/L | Affects cytokine signaling in offspring | Developmental endocrine-mediated perturbations;Immunological endocrine-mediated perturbations | |
| IVR | 2 mg/L | 2 mg/L | Changes in morphology of seminiferous tubules in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/L | 2 mg/L | Reduced sperm counts in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/L | 2 mg/L | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVR | 0.2 mg/L | 0.2 mg/L | Abnormal sperm morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:30303745 | IVTH | 0.00001 M | 0.00001 M | Affects placental function | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 M | - | No significant effects observed | - | |
| IVR | 0.0000004 M | - | No significant effects observed | - | |
| IVR | 0.00004 M | - | No significant effects observed | - | |
| IVR | 0.0004 M | - | No significant effects observed | - | |
| IVTH | 0.0001 M | 0.0001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000004 M | 0.000004 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000004 M | 0.000004 M | Pregnancy complications | Reproductive endocrine-mediated perturbations | |
| PMID:30312744 | IVR | 0.04 mg/kg | - | No significant effects observed | - |
| IVR | 4 mg/kg | 4 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:30319184 | IVR | 0.01 mg/kg | 0.01 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Decreased estrogen levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Oxidative stress in mammary gland | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Oxidative stress in ovaries | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Oxidative stress in mammary gland | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Oxidative stress in mammary gland | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Oxidative stress in ovaries | Reproductive endocrine-mediated perturbations | |
| PMID:30321649 | IVR | 5 mg/kg | 5 mg/kg | Affects sperm motility in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg | 20 mg/kg | Affects sperm motility in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects sperm motility in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| PMID:30328349 | IVTH | 0.00000003 M | - | No significant effects observed | - |
| IVTH | 0.000003 M | 0.000003 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000003 M | 0.0000003 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| PMID:30352284 | IVTH | 0.000000001 M | 0.000000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000001 M | 0.000000001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| PMID:30352396 | IVR | 40 mg/kg | 40 mg/kg | Affects iodine uptake into thyroid | Metabolic endocrine-mediated perturbations |
| IVR | 40 mg/kg | 40 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Oxidative stress in thyroid gland | Metabolic endocrine-mediated perturbations | |
| PMID:30362448 | IVR | 10 mg/kg/day | - | No significant effects observed | - |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects pancreas development | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Elevated insulin levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| PMID:30393182 | IVTH | 0.00001 M | 0.00001 M | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 M | - | No significant effects observed | - | |
| IVTH | 0.000001 M | - | No significant effects observed | - | |
| IVTH | 0.0001 M | 0.0001 M | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0003 M | 0.0003 M | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| PMID:30465772 | IVR | 0.04 mg/kg | 0.04 mg/kg | Affects neuronal density | Neurological endocrine-mediated perturbations |
| PMID:30485539 | IVTH | 0.0001 M | 0.0001 M | Prostate carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| IVTH | 0.00015 M | 0.00015 M | Prostate carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0002 M | 0.0002 M | Prostate carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00025 M | 0.00025 M | Prostate carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| PMID:30557795 | IVR | 400 mg/kg | 400 mg/kg | Affects leydig cells function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 400 mg/kg | 400 mg/kg | Affects steroidogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Affects leydig cells function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects leydig cells function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects steroidogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:30566610 | IVR | 5 mg/kg/day | 5 mg/kg/day | Elevated glucose levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects lipid metabolism in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects glucose metabolism in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| PMID:30586564 | IVR | 10000 mg/kg/day | 10000 mg/kg/day | Decrease in T4 levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations |
| IVR | 10000 mg/kg/day | 10000 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 10000 mg/kg/day | 10000 mg/kg/day | Elevated insulin levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 10000 mg/kg/day | 10000 mg/kg/day | Increased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10000 mg/kg/day | 10000 mg/kg/day | Increased progesterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10000 mg/kg/day | 10000 mg/kg/day | Increased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10000 mg/kg/day | 10000 mg/kg/day | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 10000 mg/kg/day | 10000 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10000 mg/kg/day | 10000 mg/kg/day | Decrease in T3 levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 10000 mg/kg/day | 10000 mg/kg/day | Affects thyroid function in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 50000 mg/kg/day | 50000 mg/kg/day | Elevated insulin levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 50000 mg/kg/day | 50000 mg/kg/day | Affects thyroid function in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 50000 mg/kg/day | 50000 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 50000 mg/kg/day | 50000 mg/kg/day | Decrease in corticosterone levels in offspring | Developmental endocrine-mediated | |
| IVR | 50000 mg/kg/day | 50000 mg/kg/day | Increased cholesterol levels | ||
| IVR | 50000 mg/kg/day | 50000 mg/kg/day | Affects thyroid function | ||
| PMID:30613871 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects cell metabolism | Metabolic endocrine-mediated perturbations |
| PMID:30755151 | IVR | 5 mg/kg | 5 mg/kg | Changes in morphology of seminiferous tubules in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Increased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Increased weights of epididymis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Reduced sperm counts in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Abnormal sperm morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects expression of androgen receptor (AR) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects sperm motility in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects spermatogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Alters sperm function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Affects sperm motility in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Reduced sperm counts in offspring | D | |
| PMID:30758795 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations | |
| PMID:30761779 | IVR | 0.1 mg/L | 0.1 mg/L | Decrease in T3 levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations |
| IVR | 0.1 mg/L | 0.1 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | 0.1 mg/L | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| PMID:30790712 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects the biochemical composition of liver in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects liver function | Hepatic endocrine-mediated perturbations | |
| PMID:30817060 | IVR | 23.58 mg/kg/day | 23.58 mg/kg/day | Affects anogenital distance in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 23.58 mg/kg/day | 23.58 mg/kg/day | Decreased FSH levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 23.58 mg/kg/day | 23.58 mg/kg/day | Increased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 23.58 mg/kg/day | 23.58 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00023 mg/kg/day | 0.00023 mg/kg/day | Affects anogenital distance in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.00023 mg/kg/day | 0.00023 mg/kg/day | Decreased FSH levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.00023 mg/kg/day | 0.00023 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Decreased FSH levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Increased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Affects anogenital distance in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:30817981 | IVTH | 0.00000001 M | 0.00000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 M | 0.00000001 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:30822521 | IVR | 0.04 mg/kg | 0.04 mg/kg | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Prostate hyperplasia | Reproductive endocrine-mediated perturbations | |
| PMID:30823348 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects the biochemical composition of liver in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Increased liver weights in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Increased hepatic glycogen levels in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Oxidative stress in liver in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations | |
| PMID:30851587 | IVTH | 0.00001 M | 0.00001 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| PMID:30871434 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | - | No significant effects observed | - | |
| IVR | 5 mg/kg/day | - | No significant effects observed | - | |
| PMID:30892605 | IVR | 60000 mg/kg/day | 60000 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 60000 mg/kg/day | 60000 mg/kg/day | Uterine carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 60000 mg/kg/day | 60000 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 60000 mg/kg/day | 60000 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:31064381 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Oxidative stress in nervous system | Neurological endocrine-mediated perturbations | |
| PMID:31084616 | IVR | 60 mg/kg | 60 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVR | 15 mg/kg | 15 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 120 mg/kg | 120 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 240 mg/kg | 240 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 240 mg/kg | 240 mg/kg | Increase in uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg | 30 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:31129395 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased Sex hormone-binding globulin (SHBG) levels | Reproductive endocrine-mediated perturbations | |
| PMID:31137569 | IVR | 0.25 mg/kg | 0.25 mg/kg | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| PMID:31156794 | IVR | 50 mg/kg | 50 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg | 50 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| PMID:31174228 | IVR | 40 mg/kg | 40 mg/kg | Affects thyroid function | Metabolic endocrine-mediated perturbations |
| IVR | 40 mg/kg | 40 mg/kg | Decrease in T3/T4 ratio | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| PMID:31201698 | IVR | 40 mg/kg/day | 40 mg/kg/day | Changes in morphology of seminiferous tubules in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects testicular function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Changes in morphology of seminiferous tubules in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects testicular function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Changes in morphology of seminiferous tubules in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Induce apoptosis in testis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | R | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) in offspring | ||
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects testicular function in offspring | ||
| IVR | 10 mg/kg/day | 10 mg/kg/day | Changes in morphology of seminiferous tubules in offspring | ||
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decreased estradiol levels in offspring | ||
| IVR | 10 mg/kg/day | 10 mg/kg/day | Decreased testosterone levels in offspring | ||
| IVR | 10 mg/kg/day | 10 mg/kg/day | Induce apoptosis in testis in offspring | ||
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testosterone levels in offspring | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | Induce apoptosis i | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | |||
| IVR | 40 mg/kg/day | 40 mg/kg/day | |||
| IVR | 40 mg/kg/day | 40 mg/kg/day | |||
| IVR | 40 mg/kg/day | 40 mg/kg/day | |||
| IVR | 40 mg/kg/day | 40 mg/kg/day | |||
| IVR | 40 mg/kg/day | 40 mg/kg/day | |||
| IVR | 40 mg/kg/day | 40 mg/kg/day | |||
| IVR | 40 mg/kg/day | 40 mg/kg/day | |||
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | |||
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | |||
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | |||
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | |||
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | |||
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | |||
| PMID:31230753 | IVTH | 0.00001 M | 0.00001 M | Affects placental function | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Compromised endometrial receptivity | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 M | 0.00000001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0001 M | 0.0001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| PMID:31250031 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Beta cell dysfunction | Metabolic endocrine-mediated perturbations |
| PMID:31251963 | IVR | 2.5 mg/kg/day | - | No significant effects observed | - |
| IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31278978 | IVTH | 0.00000005 M | 0.00000005 M | Affects placental function | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000005 M | 0.00000005 M | Increased hCG levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Induce apoptosis of placental cells | Reproductive endocrine-mediated perturbations | |
| PMID:31292004 | IVR | 0.002 mg/kg | 0.002 mg/kg | Increased testis weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Changes in morphology of seminiferous tubules in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Changes in morphology of seminiferous tubules in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31319301 | IVR | 16 mg/kg | 16 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations |
| IVR | 16 mg/kg | 16 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Testicular atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 16 mg/kg | 16 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 8 mg/kg | 8 mg/kg | Testicular atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 8 mg/kg | 8 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 8 mg/kg | 8 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 8 mg/kg | 8 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 8 mg/kg | 8 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Affects testicular function | Reproductive endocrine-mediated perturbations | |
| PMID:31326715 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects skeletal development | Developmental endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Hyperplasia of bone marrow | Immunological endocrine-mediated perturbations | |
| PMID:31352099 | IVTH | 0.228 mg/L | 0.228 mg/L | Increase in estradiol/testosterone ratio | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0228 mg/L | - | No significant effects observed | - | |
| IVTH | 0.00228 mg/L | - | No significant effects observed | - | |
| IVTH | 2.28 mg/L | 2.28 mg/L | Increase in estradiol/testosterone ratio | Reproductive endocrine-mediated perturbations | |
| PMID:31365888 | IVR | 25 mg/kg/day | 25 mg/kg/day | Hyperplasia in pituitary gland | Neurological endocrine-mediated perturbations |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg/day | 0.25 mg/kg/day | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg/day | 0.0025 mg/kg/day | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 2.5 mg/kg/day | 2.5 mg/kg/day | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations | |
| PMID:31369804 | IVR | 0.025 mg/kg | 0.025 mg/kg | Affects spermatogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Affects steroidogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Atrophy in seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0025 mg/kg | - | No significant effects observed | - | |
| PMID:31374317 | IVTH | 0.00001 M | 0.00001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Increased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00005 M | 0.00005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00005 M | 0.00005 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:31388671 | IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000001 M | 0.000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| PMID:31463084 | IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects prostate development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects prostate development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects steroidogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31482760 | IVR | 25 mg/kg | 25 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 25 mg/kg | 25 mg/kg | Changes in epididymal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| PMID:31503316 | IVR | 5 mg/kg/day | 5 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000025 mg/kg/day | 0.000025 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000025 mg/kg/day | 0.000025 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000025 mg/kg/day | 0.000025 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| PMID:31510804 | IVR | 10 mg/L | 10 mg/L | Increase in LH/FSH ratio | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/L | 10 mg/L | Oxidative stress in ovaries in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Elevated insulin levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Abnormal sperm morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Decreased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31549635 | IVR | 50 mg/kg/day | 50 mg/kg/day | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects vitamin D metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 250 mg/kg/day | 250 mg/kg/day | Affects vitamin D metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 250 mg/kg/day | 250 mg/kg/day | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31574244 | IVR | 0.4 mg/kg | 0.4 mg/kg | Oxidative stress in nervous system | Neurological endocrine-mediated perturbations |
| IVR | 0.04 mg/kg | 0.04 mg/kg | Neuronal degeneration | Neurological endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.4 mg/kg | 0.4 mg/kg | Neuronal degeneration | Neurological endocrine-mediated perturbations | |
| PMID:31583719 | IVR | 5 mg/kg | 5 mg/kg | Changes in morphology of seminiferous tubules in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Induce apoptosis in testis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31593881 | IVR | 40 mg/kg | 40 mg/kg | Induce apoptosis of ovarian follicles in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 40 mg/kg | 40 mg/kg | Affects ovarian function | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Pregnancy complications | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased FSH levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects ovarian function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Changes in ovarian morphology of offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Decreased LH levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects expression of estrogen receptor-beta (ER-beta) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Decreased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects expression of progesterone receptor (PR) in offspring | Developmental endocrine-mediated perturbations;Re | |
| IVR | 20 mg/kg | 20 mg/kg | Changes in ovarian morphology of offspring | ||
| IVR | 5 mg/kg | 5 mg/kg | Decreased LH levels in offspring | ||
| IVR | 20 mg/kg | 20 mg/kg | Decreased FSH levels in offspring | ||
| IVR | 20 mg/kg | 20 mg/kg | Affects expression of progesterone receptor (PR) in offspring | ||
| IVR | 20 mg/kg | 20 mg/kg | Pregnancy complications | ||
| IVR | 20 mg/kg | 20 mg/kg | Affects ovarian function in offspring | ||
| IVR | 20 mg/kg | 20 mg/kg | Decreased progesterone levels in offspring | ||
| IVR | 20 mg/kg | 20 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) in offspring | ||
| IVR | 20 mg/kg | 20 mg/kg | Affects expression of estrogen receptor-beta (ER-beta) in offspring | ||
| IVR | 20 mg/kg | 20 mg/kg | Induce apoptosis of ovarian follicles in offspring | ||
| IVR | 20 mg/kg | 20 mg/kg | |||
| IVR | 5 mg/kg | 5 mg/kg | |||
| IVR | 5 mg/kg | 5 mg/kg | |||
| IVR | 5 mg/kg | 5 mg/kg | |||
| IVR | 5 mg/kg | 5 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 10 mg/kg | 10 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 2.5 mg/kg | 2.5 mg/kg | |||
| IVR | 40 mg/kg | 40 mg/kg | |||
| IVR | 40 mg/kg | 40 mg/kg | |||
| IVR | 40 mg/kg | 40 mg/kg | |||
| IVR | 40 mg/kg | 40 mg/kg | |||
| IVR | 40 mg/kg | 40 mg/kg | |||
| IVR | 40 mg/kg | 40 mg/kg | |||
| IVR | 40 mg/kg | 40 mg/kg | |||
| IVR | 40 mg/kg | 40 mg/kg | |||
| IVR | 40 mg/kg | 40 mg/kg | |||
| PMID:31601247 | IVTH | 0.00000001 M | 0.00000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVTH | 0.000001 M | 0.000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:31606416 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased leptin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Reduced glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| PMID:31610501 | IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00001 M | 0.00001 M | Prostate carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Prostate carcinoma | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| PMID:31649729 | IVR | 0.05 mg/kg | 0.05 mg/kg | Affects brain development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| PMID:31652106 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Delayed puberty | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31697385 | IVR | 2 mg/kg/day | 2 mg/kg/day | Increased liver weights in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Changes in adrenal gland morphology in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Increased Alanine aminotransferase (ALT) levels in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Changes in morphology of thyroid gland in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Increased Aspartate aminotransferase (AST) levels in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Increase in TSH levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Increased liver weights in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Changes in adrenal gland morphology in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Changes in morphology of thyroid gland in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Increase in TSH levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Decreased brain weights in offspring | Developmental endocrine-mediated pertu | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Decreased estradiol levels in offspring | ||
| IVR | 6 mg/kg/day | 6 mg/kg/day | Increased LH levels in offspring | ||
| IVR | 18 mg/kg/day | 18 mg/kg/day | Affects uterine morphology in offspring | ||
| IVR | 18 mg/kg/day | 18 mg/kg/day | Changes in morphology of seminiferous tubules in offspring | ||
| IVR | 18 mg/kg/day | 18 mg/kg/day | Increased LH levels in offspring | ||
| IVR | 18 mg/kg/day | 18 mg/kg/day | Increased testosterone levels in offspring | ||
| IVR | 18 mg/kg/day | 18 mg/kg/day | Decreased leptin levels | ||
| IVR | 18 mg/kg/day | 18 mg/kg/day | Changes in morphology of thyroid gland in offspring | ||
| IVR | 18 mg/kg/day | 18 mg/kg/day | Increase in TSH levels in offspring | ||
| IVR | 18 mg/kg/day | 18 mg/kg/day | Increased weights of adrenal gland in offspring | ||
| IVR | 18 mg/kg/day | 18 mg/kg/day | Increased Alanine aminotransferase (ALT) levels in offspr | ||
| IVR | 18 mg/kg/day | 18 mg/kg/day | |||
| IVR | 18 mg/kg/day | 18 mg/kg/day | |||
| IVR | 18 mg/kg/day | 18 mg/kg/day | |||
| IVR | 18 mg/kg/day | 18 mg/kg/day | |||
| IVR | 18 mg/kg/day | 18 mg/kg/day | |||
| PMID:31715463 | IVR | 0.001 mg/kg | 0.001 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations |
| IVR | 0.001 mg/kg | 0.001 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg | 0.001 mg/kg | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg | 0.001 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg | 0.001 mg/kg | Decreased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg | 0.001 mg/kg | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Decreased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Reduced glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Decreased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Decreased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Decreased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects the biochemical composition of liver | Hepatic | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Decreased liver weights | ||
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects fatty acid metabolism | ||
| PMID:31745802 | IVR | 130 mg/kg/day | 130 mg/kg/day | Changes in liver morphology | Hepatic endocrine-mediated perturbations |
| IVR | 130 mg/kg/day | 130 mg/kg/day | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 130 mg/kg/day | 130 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| PMID:31753310 | IVR | 0.05 mg/kg | 0.05 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| PMID:31771501 | IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Prostate hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 0.09 mg/kg/day | 0.09 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.09 mg/kg/day | 0.09 mg/kg/day | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.09 mg/kg/day | 0.09 mg/kg/day | Prostate hyperplasia | Reproductive endocrine-mediated perturbations | |
| PMID:31793690 | IVR | 1 mg/kg | 1 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects survival of germ cells | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:31875995 | IVTH | 0.000045 M | 0.000045 M | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations |
| IVTH | 0.000045 M | 0.000045 M | Oxidative stress in prostate | Reproductive endocrine-mediated perturbations | |
| PMID:31912924 | IVR | 1 mg/kg | 1 mg/kg | Affects survival of germ cells | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:31917966 | IVR | 0.05 mg/kg | 0.05 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:9449681 | IVTH | 0.0000000001 - 0.00000001 M | 0.0000000001 - 0.00000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000000001 - 0.00000001 M | 0.0000000001 - 0.00000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| PMID:9460178 | IVR | 0.002 mg/kg | 0.002 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Alterations in preputial separation | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.